14
Participants
Start Date
March 9, 2021
Primary Completion Date
December 8, 2022
Study Completion Date
April 27, 2023
KF-0210 tablets, 120 mg
KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
KF-0210 tablets, 240 mg
KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
KF-0210 tablets, 450 mg
KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
KF-0210 tablets, 600 mg
KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
KF-0210 (dosage RP2D-2) + Atezolizumab
KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
KF-0210 (dosage RP2D-1) + Atezolizumab
KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
KF-0210 (dosage RP2D) + Atezolizumab
KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Scientia Clinical Research Limited, Randwick
Keythera Pharmaceuticals (Australia) Pty Ltd
INDUSTRY